Profiles

Keywords
Last Name
Institution

John Somberg

Concepts (588)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Anti-Arrhythmia Agents
55
2016
89
8.820
Why?
Drug Approval
19
2013
33
6.690
Why?
United States Food and Drug Administration
36
2014
70
6.570
Why?
Drug Industry
21
2013
28
5.100
Why?
Electrocardiography
49
2015
197
4.680
Why?
Clinical Trials as Topic
26
2014
364
4.580
Why?
United States
72
2014
1960
4.440
Why?
Amiodarone
18
2016
28
4.240
Why?
Pharmaceutical Preparations
10
2012
18
4.180
Why?
Arrhythmias, Cardiac
36
2010
126
4.140
Why?
Humans
213
2018
25275
3.940
Why?
Device Approval
8
2014
16
3.890
Why?
Drug-Related Side Effects and Adverse Reactions
12
2018
32
3.610
Why?
Heart Failure
14
2015
176
3.150
Why?
Drug Design
6
2014
36
3.050
Why?
Tachycardia
33
2013
43
2.930
Why?
Equipment Design
8
2014
175
2.790
Why?
Research
12
2014
59
2.740
Why?
Equipment and Supplies
5
2011
14
2.650
Why?
Diuretics
6
2009
13
2.590
Why?
Drug Prescriptions
8
2008
23
2.570
Why?
Hypertension
8
2015
209
2.490
Why?
Atrial Fibrillation
9
2016
118
2.270
Why?
Long QT Syndrome
7
2011
13
2.230
Why?
Ether-A-Go-Go Potassium Channels
5
2008
8
2.090
Why?
Caffeine
3
2015
61
2.080
Why?
Cardiovascular Agents
6
2015
24
2.080
Why?
Periodicals as Topic
5
2015
34
2.010
Why?
Sotalol
7
2016
7
2.000
Why?
Endpoint Determination
4
2014
27
1.860
Why?
Patents as Topic
4
2014
5
1.810
Why?
Blood Pressure
18
2015
191
1.770
Why?
Cardiovascular Diseases
7
2014
293
1.730
Why?
Publishing
4
2015
34
1.650
Why?
Drug Labeling
4
2010
6
1.580
Why?
Politics
5
2010
18
1.570
Why?
Research Support as Topic
5
2013
20
1.570
Why?
Legislation, Drug
5
2008
5
1.540
Why?
Myocardial Infarction
10
2009
163
1.480
Why?
Drug Costs
5
2015
16
1.470
Why?
Biomedical Research
4
2013
75
1.440
Why?
Delivery of Health Care
3
2015
68
1.410
Why?
Advisory Committees
3
2013
35
1.380
Why?
Central Nervous System Stimulants
2
2015
55
1.380
Why?
Analgesics
2
2015
73
1.350
Why?
Chronic Pain
2
2015
64
1.340
Why?
Product Surveillance, Postmarketing
7
2010
17
1.320
Why?
Drug Therapy
5
2012
15
1.270
Why?
Piperidines
17
1987
32
1.250
Why?
Financing, Government
4
2013
14
1.240
Why?
Heart Rate
17
2015
131
1.240
Why?
Disease Outbreaks
3
2014
88
1.200
Why?
Risk Assessment
6
2014
664
1.180
Why?
Conflict of Interest
3
2013
17
1.150
Why?
Vasodilator Agents
5
2009
28
1.140
Why?
Infusions, Intravenous
10
2011
93
1.100
Why?
Female
69
2015
14955
1.090
Why?
Male
73
2015
14662
1.060
Why?
Angiotensin-Converting Enzyme Inhibitors
5
2002
27
1.030
Why?
Hypotension
4
2005
23
1.030
Why?
Health Care Reform
2
2011
17
1.000
Why?
Health Policy
3
2014
41
0.980
Why?
Benzeneacetamides
11
1986
12
0.960
Why?
Evidence-Based Medicine
4
2009
194
0.960
Why?
Quinidine
12
2007
14
0.960
Why?
Genetic Testing
3
2012
72
0.960
Why?
Animals
27
2009
4713
0.950
Why?
Randomized Controlled Trials as Topic
3
2014
282
0.950
Why?
Ethacrynic Acid
2
2009
3
0.930
Why?
Lidocaine
12
2004
34
0.920
Why?
Edema
2
2009
35
0.910
Why?
Oocytes
6
2008
14
0.900
Why?
Internet
2
2015
80
0.870
Why?
Electrophysiology
18
2007
146
0.850
Why?
Sex Characteristics
3
2015
88
0.850
Why?
Drug Combinations
2
2015
79
0.830
Why?
Stroke
2
2011
305
0.820
Why?
Time Factors
19
2012
1620
0.810
Why?
Dose-Response Relationship, Drug
14
2010
492
0.810
Why?
Potassium Channels, Voltage-Gated
3
2006
12
0.800
Why?
Procainamide
19
1987
20
0.790
Why?
Education, Medical, Continuing
2
2008
42
0.790
Why?
Drug Interactions
6
2010
66
0.780
Why?
Digoxin
3
2014
6
0.780
Why?
Platelet Aggregation Inhibitors
4
2010
58
0.770
Why?
Hypoglycemic Agents
2
2010
63
0.760
Why?
Hemodynamics
11
2004
87
0.750
Why?
Diffusion of Innovation
2
2008
35
0.750
Why?
Aminobutyrates
1
2015
1
0.740
Why?
Tetrazoles
1
2015
6
0.740
Why?
Energy Drinks
1
2015
1
0.740
Why?
Syncope, Vasovagal
2
2009
2
0.740
Why?
Coffee
1
2015
3
0.740
Why?
Drug Utilization
3
2006
22
0.730
Why?
Manometry
1
2015
27
0.730
Why?
Nicotine
1
2015
8
0.730
Why?
Thyroid Gland
1
2016
55
0.730
Why?
Research Design
3
2007
180
0.720
Why?
Global Health
2
2014
51
0.720
Why?
Kidney
2
2015
174
0.720
Why?
Diabetic Neuropathies
1
2015
13
0.720
Why?
Myocardial Ischemia
3
2009
50
0.720
Why?
Flecainide
9
2008
12
0.710
Why?
Denervation
1
2015
18
0.710
Why?
Computers
1
2015
19
0.700
Why?
Endothelium, Vascular
1
2015
70
0.700
Why?
Death, Sudden, Cardiac
3
2000
23
0.700
Why?
Middle Aged
52
2010
9439
0.700
Why?
Hemorrhagic Fever, Ebola
1
2014
8
0.690
Why?
Sports
2
2008
19
0.690
Why?
Adult
29
2015
8233
0.680
Why?
Biological Products
2
2007
28
0.680
Why?
Defibrillators, Implantable
2
2013
19
0.670
Why?
Public Health
1
2014
45
0.670
Why?
Practice Guidelines as Topic
2
2012
330
0.670
Why?
Medical Device Recalls
1
2014
3
0.670
Why?
Angioplasty, Balloon, Coronary
2
2009
55
0.660
Why?
Pain Management
1
2015
97
0.660
Why?
Heart Valve Prosthesis
1
2014
30
0.650
Why?
Antibodies, Monoclonal
2
2007
302
0.650
Why?
Patient Care
1
2014
30
0.650
Why?
Communication
1
2015
89
0.650
Why?
Sulfonamides
4
2016
56
0.640
Why?
Supreme Court Decisions
1
2013
1
0.640
Why?
Equipment Safety
2
2010
13
0.640
Why?
Quality Assurance, Health Care
1
2014
52
0.630
Why?
Federal Government
1
2013
4
0.630
Why?
Guidelines as Topic
1
2014
62
0.630
Why?
Patient Protection and Affordable Care Act
1
2013
17
0.630
Why?
Genes, BRCA1
1
2013
12
0.630
Why?
Piperazines
3
2009
83
0.630
Why?
Genes, BRCA2
1
2013
12
0.620
Why?
Electrocardiography, Ambulatory
3
2015
20
0.620
Why?
Torsades de Pointes
3
2011
11
0.620
Why?
Comparative Effectiveness Research
1
2013
7
0.610
Why?
Tachycardia, Ventricular
2
2004
24
0.610
Why?
Cardiac Pacing, Artificial
16
1987
47
0.610
Why?
Xenopus laevis
6
2008
10
0.610
Why?
Registries
2
2004
148
0.610
Why?
Action Potentials
4
2006
112
0.590
Why?
Metagenome
1
2012
20
0.590
Why?
Diabetes Mellitus
2
2011
100
0.590
Why?
Drug and Narcotic Control
2
2010
8
0.580
Why?
Bioterrorism
2
2002
6
0.570
Why?
Antithrombins
1
2011
6
0.560
Why?
Drugs, Generic
2
2002
4
0.560
Why?
Drug Delivery Systems
2
2015
35
0.560
Why?
Therapies, Investigational
1
2011
4
0.550
Why?
Risk Factors
9
2016
2162
0.550
Why?
Cross Infection
1
2014
262
0.540
Why?
Hypotension, Orthostatic
2
2010
16
0.540
Why?
Pediatrics
2
2003
50
0.540
Why?
Anticholesteremic Agents
2
2008
21
0.540
Why?
Drug Discovery
1
2011
26
0.540
Why?
Heart Conduction System
7
2002
26
0.530
Why?
Cyclooxygenase Inhibitors
3
2006
37
0.530
Why?
Product Recalls and Withdrawals
1
2010
1
0.520
Why?
Fibrinolytic Agents
1
2011
85
0.520
Why?
Sympathomimetics
1
2010
5
0.520
Why?
Midodrine
1
2010
2
0.520
Why?
Administration, Oral
12
2016
143
0.520
Why?
Adrenergic beta-Antagonists
7
2016
36
0.520
Why?
Drug Evaluation
10
2002
56
0.510
Why?
Aged
39
2010
8370
0.510
Why?
Antihypertensive Agents
3
2014
62
0.510
Why?
Angina Pectoris
2
2004
17
0.510
Why?
Potassium
2
2007
66
0.510
Why?
Hospitalization
2
2014
259
0.510
Why?
Chemistry, Pharmaceutical
4
2005
14
0.500
Why?
Cytochrome P-450 Enzyme System
1
2010
10
0.500
Why?
Global Warming
1
2010
1
0.500
Why?
Decision Making
1
2012
174
0.490
Why?
Anticoagulants
1
2011
121
0.490
Why?
Therapeutic Equivalency
5
2016
8
0.490
Why?
Dementia, Vascular
1
2010
39
0.490
Why?
Muscle Contraction
2
2007
82
0.490
Why?
Technetium
1
2009
6
0.490
Why?
Cost Control
1
2009
11
0.480
Why?
Thiophenes
1
2009
14
0.480
Why?
Heart Ventricles
18
2008
187
0.480
Why?
Technology, Pharmaceutical
1
2009
2
0.480
Why?
Ventricular Function
2
2008
14
0.480
Why?
Radiopharmaceuticals
1
2009
55
0.470
Why?
Neurology
1
2011
95
0.470
Why?
Insulin
1
2010
89
0.470
Why?
Ascites
1
2009
5
0.470
Why?
Medication Errors
2
2000
18
0.470
Why?
Genetics
2
2006
2
0.460
Why?
Natriuretic Peptide, Brain
2
2006
10
0.460
Why?
Methadone
1
2008
7
0.460
Why?
Patient Selection
2
2007
225
0.460
Why?
Licensure, Medical
1
2008
1
0.460
Why?
Catheter Ablation
1
2009
44
0.450
Why?
Catheterization
1
2009
59
0.450
Why?
Drug-Eluting Stents
1
2008
11
0.450
Why?
Acidosis
2
2005
4
0.450
Why?
Rats
7
2007
927
0.450
Why?
Authorship
1
2008
13
0.450
Why?
Clinical Trials, Phase I as Topic
1
2008
9
0.440
Why?
Substance Abuse Detection
1
2008
5
0.440
Why?
Street Drugs
1
2008
9
0.440
Why?
Self Disclosure
1
2008
12
0.440
Why?
Fees and Charges
1
2008
7
0.440
Why?
Enzyme Inhibitors
1
2009
151
0.440
Why?
Doping in Sports
1
2008
2
0.440
Why?
Signal Processing, Computer-Assisted
1
2008
44
0.440
Why?
Hypercholesterolemia
1
2008
29
0.430
Why?
Food-Drug Interactions
1
2007
1
0.430
Why?
Flavanones
1
2007
3
0.430
Why?
Hypolipidemic Agents
2
2014
27
0.430
Why?
Beverages
1
2007
14
0.430
Why?
Analgesics, Opioid
1
2008
80
0.430
Why?
Heart Diseases
2
2008
87
0.420
Why?
Government Regulation
3
2015
7
0.420
Why?
Ethics Consultation
1
2007
1
0.420
Why?
Heart Septal Defects, Atrial
1
2007
23
0.410
Why?
Metolazone
1
2007
1
0.410
Why?
Diuresis
1
2007
2
0.410
Why?
Physician's Role
1
2007
19
0.410
Why?
Furosemide
1
2007
2
0.410
Why?
Graft Occlusion, Vascular
1
2007
21
0.400
Why?
Myocardial Contraction
5
2005
75
0.400
Why?
Databases as Topic
1
2006
20
0.400
Why?
Social Control, Formal
3
2001
3
0.400
Why?
Retrospective Studies
6
2015
2518
0.400
Why?
Patch-Clamp Techniques
4
2007
135
0.390
Why?
Gastrointestinal Tract
1
2007
49
0.390
Why?
Pharmacology, Clinical
2
2004
3
0.390
Why?
Electrodes
1
2006
16
0.390
Why?
Information Dissemination
2
2004
19
0.380
Why?
Electric Stimulation
12
2004
86
0.380
Why?
In Vitro Techniques
4
2007
253
0.380
Why?
Security Measures
2
2003
4
0.380
Why?
Erythromycin
1
2006
16
0.380
Why?
Verapamil
7
2009
33
0.380
Why?
Hypnotics and Sedatives
1
2006
21
0.370
Why?
Natriuretic Agents
1
2005
1
0.370
Why?
Hyperkalemia
2
2006
5
0.370
Why?
Pyridines
1
2006
44
0.370
Why?
Administration, Topical
2
2015
20
0.360
Why?
Water
2
2003
35
0.360
Why?
Hypokalemia
2
2005
7
0.360
Why?
Healthy Volunteers
2
2015
36
0.360
Why?
Magnesium Sulfate
1
2005
7
0.360
Why?
Prostheses and Implants
1
2007
160
0.360
Why?
Human Experimentation
2
2002
2
0.360
Why?
Young Adult
4
2015
1782
0.350
Why?
Antineoplastic Agents
2
2009
292
0.350
Why?
Stents
1
2007
149
0.350
Why?
Coronary Disease
4
1998
93
0.350
Why?
Ethics, Medical
2
2001
17
0.340
Why?
Anti-Obesity Agents
1
2004
6
0.340
Why?
Liability, Legal
3
2012
6
0.340
Why?
Rats, Sprague-Dawley
4
2007
474
0.340
Why?
Heart Arrest
4
1997
44
0.330
Why?
Nonprescription Drugs
1
2004
2
0.330
Why?
Prescription Fees
1
2003
1
0.330
Why?
Imidazoles
6
1987
64
0.330
Why?
Stereoisomerism
4
2008
22
0.320
Why?
Sensitivity and Specificity
4
2008
562
0.320
Why?
Publication Bias
1
2003
6
0.320
Why?
Adverse Drug Reaction Reporting Systems
2
2000
8
0.320
Why?
Communicable Diseases, Emerging
1
2003
2
0.320
Why?
Severe Acute Respiratory Syndrome
1
2003
5
0.320
Why?
Teaching
1
2004
60
0.320
Why?
Electric Countershock
5
2013
20
0.310
Why?
Drug Administration Schedule
6
2010
246
0.310
Why?
Clinical Protocols
2
2003
58
0.310
Why?
Blood Pressure Monitoring, Ambulatory
1
2003
4
0.310
Why?
Glyburide
1
2002
2
0.310
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2004
61
0.300
Why?
Metformin
1
2002
10
0.300
Why?
Clinical Competence
1
2005
228
0.300
Why?
Drug Therapy, Combination
4
2009
247
0.300
Why?
Anti-Bacterial Agents
2
2006
366
0.290
Why?
Polymorphism, Genetic
2
2002
89
0.290
Why?
Facility Regulation and Control
1
2002
2
0.290
Why?
1-Octanol
1
2002
1
0.290
Why?
Solvents
1
2002
5
0.290
Why?
Heart Valve Diseases
1
2002
14
0.290
Why?
Public Health Administration
1
2001
9
0.280
Why?
Disaster Planning
1
2001
8
0.280
Why?
Magnesium Compounds
1
2001
1
0.280
Why?
Emergency Medical Services
1
2001
34
0.270
Why?
Accreditation
1
2001
12
0.270
Why?
Calcium Metabolism Disorders
1
2001
1
0.270
Why?
Orphan Drug Production
1
2001
3
0.270
Why?
Ventricular Dysfunction
1
2001
3
0.270
Why?
Stem Cells
1
2001
48
0.270
Why?
Addison Disease
1
2000
1
0.260
Why?
Government Programs
1
2000
2
0.260
Why?
Obesity
1
2004
271
0.260
Why?
Cross-Over Studies
2
2010
66
0.250
Why?
Genetic Markers
3
2012
49
0.250
Why?
Diabetes Mellitus, Type 2
1
2002
180
0.250
Why?
Information Services
1
1999
5
0.240
Why?
Science
1
1999
5
0.240
Why?
Half-Life
4
2009
16
0.240
Why?
Potassium Channels
3
2006
42
0.240
Why?
Pharmacokinetics
2
2002
6
0.230
Why?
Circadian Rhythm
2
2006
258
0.230
Why?
Dogs
5
2004
244
0.220
Why?
Drug Hypersensitivity
1
1998
15
0.220
Why?
Biological Availability
3
2009
24
0.220
Why?
Area Under Curve
2
2010
65
0.220
Why?
Delayed Rectifier Potassium Channels
2
2007
5
0.220
Why?
Alprostadil
1
1997
11
0.220
Why?
Peripheral Vascular Diseases
1
1997
11
0.210
Why?
Aged, 80 and over
6
2004
4259
0.210
Why?
Arterial Occlusive Diseases
1
1997
17
0.210
Why?
Death, Sudden
4
2004
15
0.210
Why?
Heart
5
1992
96
0.200
Why?
Hypertrophy, Left Ventricular
1
1997
28
0.200
Why?
Nitroglycerin
2
1995
4
0.200
Why?
Universities
2
2010
20
0.190
Why?
Risk
4
2011
204
0.190
Why?
Hydrogen-Ion Concentration
2
2007
181
0.190
Why?
Controlled Clinical Trials as Topic
2
2008
6
0.190
Why?
Hydantoins
2
2006
2
0.190
Why?
Imidazolidines
2
2006
2
0.190
Why?
Phenethylamines
2
2006
5
0.190
Why?
Treatment Outcome
4
2008
3134
0.190
Why?
Biotechnology
1
2015
3
0.190
Why?
Hypercalcemia
3
2001
8
0.190
Why?
Adolescent
2
2015
2270
0.190
Why?
Reproducibility of Results
3
2006
732
0.190
Why?
Injections, Intravenous
7
2016
53
0.190
Why?
Diclofenac
1
2015
4
0.180
Why?
Membrane Potentials
2
2007
216
0.180
Why?
Stimulation, Chemical
1
2015
14
0.180
Why?
Ointments
1
2015
3
0.180
Why?
Hypothyroidism
1
2016
63
0.180
Why?
Myocardium
4
2008
170
0.180
Why?
Antibodies, Monoclonal, Humanized
2
2007
106
0.180
Why?
Africa South of the Sahara
1
2014
1
0.180
Why?
Anilides
4
1987
9
0.170
Why?
Sex Factors
2
2008
421
0.170
Why?
Journalism, Medical
2
2008
5
0.170
Why?
Ventricular Fibrillation
5
2006
23
0.170
Why?
Breast Neoplasms
2
2013
386
0.170
Why?
Europe
2
2005
69
0.170
Why?
Phenothiazines
4
1987
4
0.170
Why?
Early Termination of Clinical Trials
1
2014
2
0.170
Why?
Referral and Consultation
1
2015
84
0.170
Why?
Structure-Activity Relationship
2
2005
54
0.160
Why?
Safety
1
2014
53
0.160
Why?
Lobbying
1
2013
1
0.160
Why?
Health Insurance Exchanges
1
2013
1
0.160
Why?
Ouabain
4
1983
6
0.160
Why?
Electricity
1
2013
10
0.160
Why?
Organizational Innovation
2
2003
19
0.150
Why?
Isradipine
1
1993
3
0.150
Why?
Pyrrolidines
4
1985
15
0.150
Why?
Pain Measurement
1
2015
368
0.150
Why?
Bradycardia
2
2005
20
0.150
Why?
Solubility
2
2003
38
0.150
Why?
Investigational New Drug Application
1
1992
1
0.150
Why?
Monitoring, Physiologic
4
2008
81
0.150
Why?
International Cooperation
2
2005
36
0.150
Why?
Electric Stimulation Therapy
1
2013
43
0.150
Why?
Competitive Behavior
1
2012
6
0.150
Why?
Cardiomyopathies
1
2013
31
0.150
Why?
Economics, Pharmaceutical
2
2003
6
0.150
Why?
Unnecessary Procedures
1
2013
25
0.150
Why?
Thallium Radioisotopes
1
1992
4
0.150
Why?
Dipyridamole
1
1992
4
0.150
Why?
Double-Blind Method
5
2002
464
0.150
Why?
Patient Safety
1
2013
41
0.150
Why?
Chemoprevention
1
2011
6
0.140
Why?
Vitamin K
1
2011
6
0.140
Why?
Factor Xa Inhibitors
1
2011
5
0.140
Why?
Prosthesis Design
1
2014
420
0.140
Why?
Disease Models, Animal
2
2006
691
0.140
Why?
Safety-Based Medical Device Withdrawals
1
2011
1
0.140
Why?
Comorbidity
2
2011
471
0.130
Why?
Molecular Biology
1
2011
14
0.130
Why?
Equipment Failure
1
2011
46
0.130
Why?
Paternalism
1
2010
1
0.130
Why?
Public Policy
2
2001
5
0.130
Why?
Cell- and Tissue-Based Therapy
1
2011
14
0.130
Why?
Florida
1
2010
17
0.130
Why?
Coronary Artery Disease
2
2004
125
0.130
Why?
Bethanidine
3
1985
3
0.130
Why?
Acute Disease
2
2009
253
0.130
Why?
Medicaid
1
2011
35
0.130
Why?
Ticlopidine
1
2010
14
0.130
Why?
Medicare
1
2011
71
0.130
Why?
Industry
1
2010
9
0.130
Why?
Quality of Health Care
1
2012
118
0.130
Why?
Exercise Test
5
1995
99
0.120
Why?
Publications
1
2010
8
0.120
Why?
Health Care Costs
1
2011
70
0.120
Why?
Radioisotopes
1
2009
15
0.120
Why?
Lithium Carbonate
2
2000
4
0.120
Why?
Canada
1
2009
44
0.120
Why?
Antimanic Agents
2
2000
12
0.120
Why?
Linear Models
1
2010
255
0.120
Why?
Hepatorenal Syndrome
1
2009
1
0.120
Why?
Glaucoma
1
2009
5
0.120
Why?
Ultrafiltration
1
2009
6
0.120
Why?
Vasoconstrictor Agents
1
2009
22
0.120
Why?
Glutathione Transferase
1
2009
8
0.120
Why?
Hepatic Encephalopathy
1
2009
6
0.120
Why?
Computer Simulation
1
2010
213
0.120
Why?
Radiation-Sensitizing Agents
1
2009
13
0.120
Why?
Pacemaker, Artificial
1
2009
21
0.120
Why?
National Institutes of Health (U.S.)
1
2009
27
0.120
Why?
Liver Failure
1
2009
13
0.120
Why?
Renal Insufficiency
1
2009
18
0.110
Why?
Protein Isoforms
1
2008
52
0.110
Why?
Bipolar Disorder
2
2000
112
0.110
Why?
Drug Resistance, Neoplasm
1
2009
58
0.110
Why?
Cotinine
1
2008
5
0.110
Why?
Azetidines
1
2008
4
0.110
Why?
Research Subjects
1
2008
9
0.110
Why?
Prognosis
2
2009
826
0.110
Why?
Commerce
1
2008
9
0.110
Why?
Simvastatin
1
2008
15
0.110
Why?
Quality Control
1
2008
46
0.110
Why?
Citrus paradisi
1
2007
1
0.110
Why?
Xenopus
1
2007
6
0.110
Why?
Mental Processes
1
2008
17
0.110
Why?
Maximum Tolerated Dose
1
2007
21
0.110
Why?
Anti-Inflammatory Agents
1
2009
92
0.110
Why?
Legislation, Medical
1
2007
1
0.100
Why?
Patient Readmission
1
2009
89
0.100
Why?
Motivation
1
2008
89
0.100
Why?
Child
2
2003
1315
0.100
Why?
Natriuresis
1
2007
3
0.100
Why?
Injections, Intraperitoneal
1
2007
13
0.100
Why?
Prospective Studies
2
2004
1448
0.100
Why?
Quinolines
1
2007
15
0.100
Why?
Cyclooxygenase 2 Inhibitors
1
2007
28
0.100
Why?
Access to Information
1
2006
5
0.100
Why?
Confidentiality
1
2006
9
0.100
Why?
Substance-Related Disorders
1
2008
102
0.100
Why?
Coated Materials, Biocompatible
1
2007
43
0.100
Why?
Smoking
1
2008
166
0.100
Why?
Predictive Value of Tests
1
2009
535
0.100
Why?
Databases, Factual
1
2008
256
0.100
Why?
Blood Vessel Prosthesis Implantation
1
2007
40
0.100
Why?
Probability
1
2006
92
0.100
Why?
Ethanol
1
2008
120
0.100
Why?
Extracellular Matrix
1
2006
90
0.090
Why?
Enterococcus faecalis
1
2006
8
0.090
Why?
Muscle, Smooth
1
2006
15
0.090
Why?
Benzofurans
1
1986
4
0.090
Why?
Acecainide
1
1985
1
0.090
Why?
Tocainide
4
1986
4
0.090
Why?
Antidepressive Agents
2
2004
91
0.090
Why?
Microbial Sensitivity Tests
1
2006
110
0.090
Why?
Extracellular Fluid
1
2005
4
0.090
Why?
Gene Expression Profiling
1
2006
153
0.090
Why?
Aspirin
1
2006
65
0.090
Why?
Feasibility Studies
1
2006
210
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2006
89
0.090
Why?
Incidence
1
2008
673
0.090
Why?
Lethal Dose 50
1
2005
2
0.090
Why?
Trans-Activators
1
2005
30
0.090
Why?
Bepridil
4
1985
4
0.090
Why?
Stroke Volume
3
1999
48
0.090
Why?
Influenza Vaccines
1
2004
9
0.090
Why?
Lactones
1
2004
13
0.090
Why?
Sulfones
1
2004
24
0.090
Why?
Guanidines
1
1984
2
0.090
Why?
Follow-Up Studies
4
2002
1745
0.090
Why?
National Library of Medicine (U.S.)
1
2004
1
0.090
Why?
Recombinant Proteins
1
2005
291
0.090
Why?
Colon
1
2006
131
0.080
Why?
Pharmaceutical Solutions
1
2004
2
0.080
Why?
Aconitine
1
2004
1
0.080
Why?
Self Medication
1
2004
3
0.080
Why?
Sleep Initiation and Maintenance Disorders
1
2006
90
0.080
Why?
Cells, Cultured
1
2006
756
0.080
Why?
Purkinje Fibers
1
1983
2
0.080
Why?
Education, Medical, Undergraduate
1
2004
29
0.080
Why?
Delayed-Action Preparations
1
2003
36
0.080
Why?
Disease Susceptibility
1
2004
67
0.080
Why?
Oligonucleotide Array Sequence Analysis
1
2004
77
0.080
Why?
SARS Virus
1
2003
4
0.080
Why?
Communicable Disease Control
1
2003
9
0.080
Why?
World Health Organization
1
2003
18
0.080
Why?
Travel
1
2003
14
0.080
Why?
Algorithms
1
2006
377
0.080
Why?
Spinal Cord
3
1980
96
0.080
Why?
Australia
1
2003
38
0.080
Why?
Encainide
4
1987
7
0.080
Why?
Centers for Disease Control and Prevention (U.S.)
1
2002
21
0.080
Why?
Moricizine
4
1987
6
0.070
Why?
Baltimore
1
2002
15
0.070
Why?
Ethics Committees, Research
1
2002
4
0.070
Why?
Ventricular Function, Left
1
2002
54
0.070
Why?
Biological Warfare
1
2002
3
0.070
Why?
Indicators and Reagents
1
2002
20
0.070
Why?
Treatment Failure
1
2002
157
0.070
Why?
Chronic Disease
2
1999
458
0.070
Why?
Chromatography, High Pressure Liquid
1
2002
43
0.070
Why?
Civil Defense
1
2002
8
0.070
Why?
Cardiac Complexes, Premature
3
1986
3
0.070
Why?
Digitalis Glycosides
2
2001
3
0.070
Why?
Age Factors
1
2004
773
0.070
Why?
Ethics Committees
1
2001
2
0.070
Why?
Professional Staff Committees
1
2001
9
0.070
Why?
Awareness
1
2001
41
0.070
Why?
Cost-Benefit Analysis
1
2002
121
0.070
Why?
Disopyramide
3
1986
3
0.070
Why?
Hypocalcemia
1
2001
4
0.070
Why?
Informed Consent
1
2001
24
0.070
Why?
Intestinal Absorption
1
2001
43
0.070
Why?
Cognition Disorders
1
2010
1035
0.070
Why?
Tilt-Table Test
1
2000
1
0.070
Why?
Histamine Antagonists
1
1980
2
0.070
Why?
Academic Medical Centers
1
2001
129
0.060
Why?
Decision Making, Computer-Assisted
1
2000
6
0.060
Why?
Aging
1
2010
1251
0.060
Why?
Propranolol
2
1979
13
0.060
Why?
Analysis of Variance
1
2001
357
0.060
Why?
Prevalence
1
2002
473
0.060
Why?
Abstracting and Indexing as Topic
1
1999
4
0.060
Why?
Information Storage and Retrieval
1
1999
6
0.060
Why?
Recurrence
3
1991
327
0.060
Why?
Morbidity
1
1999
54
0.060
Why?
Single-Blind Method
1
1999
116
0.060
Why?
Forecasting
1
1999
116
0.060
Why?
Drug Therapy, Computer-Assisted
1
1998
6
0.060
Why?
Needs Assessment
1
1998
49
0.050
Why?
Resuscitation
1
1997
13
0.050
Why?
Diagnosis, Computer-Assisted
1
1997
17
0.050
Why?
Atrial Flutter
2
1986
13
0.050
Why?
Isosorbide Dinitrate
1
1996
1
0.050
Why?
Echocardiography
1
1997
172
0.050
Why?
Phenytoin
2
1986
11
0.050
Why?
Administration, Sublingual
1
1995
1
0.050
Why?
Ventricular Dysfunction, Left
1
1996
49
0.050
Why?
Data Interpretation, Statistical
1
1995
89
0.040
Why?
Mutation
1
1997
410
0.040
Why?
Infusions, Parenteral
2
1985
13
0.040
Why?
Ajmaline
2
1985
2
0.040
Why?
Aprindine
2
1985
2
0.040
Why?
Bretylium Tosylate
2
1985
2
0.040
Why?
Mexiletine
2
1985
2
0.040
Why?
Propiophenones
2
1985
3
0.040
Why?
Propafenone
2
1985
3
0.040
Why?
Severity of Illness Index
1
1999
1094
0.040
Why?
Cost Sharing
1
1992
2
0.040
Why?
Suspensions
1
1992
2
0.040
Why?
Tablets
1
1992
6
0.040
Why?
Radionuclide Imaging
1
1992
62
0.040
Why?
Metabolic Clearance Rate
1
1991
8
0.040
Why?
Tissue Distribution
1
1991
46
0.040
Why?
Liver
1
1993
194
0.030
Why?
Refractory Period, Electrophysiological
2
1987
6
0.030
Why?
Intestinal Mucosa
1
1993
210
0.030
Why?
Kinetics
3
1985
279
0.030
Why?
Drug Evaluation, Preclinical
1
1987
32
0.030
Why?
Drug Resistance
1
1987
62
0.030
Why?
Fluorobenzenes
1
1986
3
0.030
Why?
Propanolamines
1
1986
9
0.030
Why?
Wolff-Parkinson-White Syndrome
1
1986
2
0.020
Why?
Tachycardia, Paroxysmal
1
1986
3
0.020
Why?
Calcium Channel Blockers
1
1986
37
0.020
Why?
Heart Atria
2
1985
75
0.020
Why?
Central Nervous System Diseases
1
1985
16
0.020
Why?
Metabolic Diseases
1
1985
14
0.020
Why?
Protriptyline
1
1984
1
0.020
Why?
Syncope
1
1984
7
0.020
Why?
Rubidium
1
1983
6
0.020
Why?
Biological Transport, Active
1
1983
20
0.020
Why?
Cats
3
1979
75
0.020
Why?
Promethazine
1
1980
1
0.020
Why?
Cimetidine
1
1980
2
0.020
Why?
Histamine
1
1980
10
0.020
Why?
Histamine H1 Antagonists
1
1980
9
0.020
Why?
Sorbitol
1
1978
5
0.010
Why?
Isosorbide
1
1978
2
0.010
Why?
Microsatellite Repeats
1
1997
18
0.010
Why?
Pedigree
1
1997
71
0.010
Why?
Gene Frequency
1
1997
82
0.010
Why?
Heterozygote
1
1997
85
0.010
Why?
Autonomic Nervous System
1
1976
25
0.010
Why?
Random Allocation
2
1986
133
0.010
Why?
Digitoxin
1
1974
1
0.010
Why?
Catecholamines
1
1993
16
0.010
Why?
Mathematics
1
1985
34
0.010
Why?
Models, Biological
1
1985
417
0.000
Why?
Mouth Floor
1
1978
2
0.000
Why?
Guinea Pigs
1
1976
69
0.000
Why?
Tritium
1
1974
17
0.000
Why?
Somberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description